Dr Reddy's, Lupin Recall Drugs in US Due to Errors

By By Rediff Money Desk, New Delhi
Apr 22, 2025 17:27
Dr Reddy's and Lupin are recalling drugs in the US due to labelling and manufacturing errors, respectively, according to the USFDA. The recalls involve an antiepileptic drug and an antidepressant.
New Delhi, Apr 22 (PTI) Dr Reddy's Laboratories and Lupin are recalling products in the US market due to labelling and manufacturing errors, respectively, according to the US health regulator.

As per its latest Enforcement Report, US Food and Drug Administration (USFDA) said a US-based subsidiary of the Hyderabad-based drug major is recalling certain batches of a generic antiepileptic drug in the US market.

Princeton-based Dr Reddy's Laboratories, Inc is recalling 4,010 bags of Levetiracetam 0.75 pc in Sodium Chloride Injection (1,000 mg/100 mL) in the US due to labelling mix up, USFDA said.

"The infusion bag is incorrectly labelled as Levetiracetam in 0.82% Sodium Chloride Injection 500 mg/100 mL, while the aluminum overwrap packaging correctly identifies the product as Levetiracetam in 0.75% Sodium Chloride Injection 1,000 mg/100 mL," it added.

The company has issued the Class 1 nationwide (US) recall on March 13 this year, the US health regulator noted.

As per the USFDA, a Class I recall pertains to defective products that can cause serious health problems.

In a separate filing, the US health regulator said that a US-based subsidiary of Mumbai-headquartered Lupin is recalling an antidepressant medication which used in the treatment of obsessive-compulsive disorder.

Naples-based Lupin Pharmaceuticals Inc is recalling 2,724 bottles of clomiPRAMINE hydrochloride Capsules USP, 25 mg, due to "Failed Impurities/Degradation Specifications", USFDA said.

The company initiated the Class II recall on April 18, it added.
Source: PTI
Read More On:
drug recallusfdalupindr reddy'spharmaceutical recall
DISCLAIMER - This article is from a syndicated feed. The original source is responsible for accuracy, views & content ownership. Views expressed may not reflect those of rediff.com India Limited.

You May Like To Read

MORE NEWS

Telangana Secures ₹2.43 Lakh Cr Investment

Telangana inks ₹2.43 lakh crore investment deals at Global Summit. Trump Media,...

Punjab Invites Korean Firms for Investment

Punjab CM Bhagwant Mann invites Korean firms like Daewoo, GS E&C to invest in Punjab....

Odisha Assembly Passes Appropriation Bill

Odisha assembly passes Rs 17,440 crore appropriation bill for 2025-26. CM Majhi defends...

CTUIL Revokes Grid Access for 6.3 GW RE Projects

CTUIL revoked grid access for 6.3 GW renewable energy projects due to developer delays....

L&T Transfers Realty Business to L&T Realty...

Larsen & Toubro transfers its realty business to L&T Realty Properties Ltd. A phased...

Wakefit IPO Subscribed 15% on Day 1

Wakefit''s Rs 1,289-cr IPO saw 15% subscription on day 1. Retail investors showed...

Apple Fitness+ Launching in 28 New Countries

Apple Fitness+ expands to 28 new countries, including India, on December 15. Enjoy...

MSME Loan Risk: Over-Leveraged Borrowers

Report reveals sharp concentration risk in MSME loan portfolios due to over-leveraged...

Navitas & Cyient: GaN Tech for High-Power India

Navitas Semiconductor and Cyient Semiconductors partner to co-develop gallium nitride...

Abrau-Durso to Produce Wine Beverages in India

Russia''s Abrau-Durso Group plans to produce wine beverages in India with IndoBevs....

Read More »

Sectoral Indices Market Indicators Listed Companies Gainers Losers Mutual Funds Portfolio Watchlist
© 2025 Rediff.com